Amlexanox vs Tirzepatide
A side-by-side research comparison of Amlexanox and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Amlexanox | Tirzepatide |
|---|---|---|
| Full name | Amlexanox (TBK1/IKKε Inhibitor) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research / Off-label | FDA Approved |
| Mechanism | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 298.29 Da | 4,814 Da |
| Half-life | ~3-4 hours | 5 days (120 hours) |
| Bioavailability | ~70% oral | High (SubQ ~80%) |
| Typical dose | 25-100 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | 3x daily | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.